NCT04887194 2024-05-08
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Mirati Therapeutics Inc.
Phase 1 Completed
Mirati Therapeutics Inc.
Jiangsu HengRui Medicine Co., Ltd.
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
Bayer
Daiichi Sankyo
GlaxoSmithKline
Astellas Pharma Inc
Spectrum Pharmaceuticals, Inc